Concerning preserving patient access to compounded medical items.
Summary
HB26-1262, titled the "Colorado Patient Access and Compounding Clarity Act," updates Colorado law governing compounded drugs and devices. The bill states that, when done in compliance with applicable federal and state law, licensed persons may compound drugs or devices in Colorado, and both resident and nonresident pharmacies and 503B outsourcing facilities may supply compounded products to licensed health-care providers, pharmacies, facilities, and organizations. It also allows those providers and entities to obtain, dispense, or administer compounded drugs or devices supplied through those lawful channels.
The bill further directs the State Board of Pharmacy not to adopt rules that are more restrictive than applicable federal or state law for compounding. It also expands exemptions under Colorado’s new-drug sales restrictions to include drugs reviewed by an institutional review board and compounded drugs or devices made in accordance with applicable law, including FDA-recognized standards and USP sterile or nonsterile processing standards. The bill applies prospectively to conduct occurring on or after its effective date and includes a safety clause.
Impact
The bill amends Colorado Revised Statutes sections 12-280-120 and 12-280-131 to align state law more closely with federal compounding frameworks under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It broadens the statutory recognition of lawful compounding, clarifies that compliant compounding is not to be treated as manufacturing, and limits the Board of Pharmacy’s ability to impose rules that exceed federal or state requirements. The measure is intended to preserve access to compounded medical items for patients and health-care settings while reducing regulatory duplication.
Sentiment
The overall sentiment reflected in the bill text is strongly supportive of patient access, regulatory clarity, and continuity of care. The legislative declaration emphasizes that compounded sterile and nonsterile products are widely relied upon in Colorado and that modernization is needed to support patient safety and uninterrupted access to essential medications. The bill ultimately passed and was signed by the Governor, indicating broad enough support for enactment.
Contention
No committee transcript or recorded vote data was provided, so specific objections are not documented in the available materials. Based on the bill’s structure, the main area of potential contention is regulatory scope: the measure limits the State Board of Pharmacy from adopting rules more restrictive than federal and state law, which may concern regulators or others favoring tighter oversight. Another possible point of debate is the expanded protection for compounded products and nonresident facilities, which could raise questions about oversight, safety standards, and the line between compounding and manufacturing.